Similar to endometrial cancer cells, knockdown of PHLDA1 alone, by 48-hr treatment with small interfering RNA (siRNA), was sufficient to generate de novo resistance to trastuzumab (Figures 6B and S5A). The gene discussed is PHLDA1; the disease is endometrial cancer.